Skip to main content
Premium Trial:

Request an Annual Quote

LifeSpan Signs Aventis as Subscriber to GPCR Database

NEW YORK, Oct. 9 – LifeSpan BioSciences of Seattle said Tuesday it had signed Aventis Pharma as its sixth subscriber to its G protein-coupled receptors database.

The database Lifespan will provide to Aventis of Strasbourg, France, includes information on non-olfactory GPCRs. The database, which is designed to help users to identify and prioritize potential drug targets, was designed to be used by Aventis’ branches in the US, Germany, and France.

"We are now mapping the top 320 GPCRs of potential therapeutic interest,” Joseph Brown, CEO of LifeSpan BioSciences, said in a statement. 

GPCRs comprise a family of cell-surface molecules that act as receptors for many biologically active compounds and pharmaceuticals. 

LifeSpan’s other subscribers are Pfizer, Merck, Bristol-Myers Squibb, Novartis Research Foundation, and Sanofi-Snythelabo.

Financial terms of the deal were not disclosed.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.